|Day Low/High||65.85 / 68.00|
|52 Wk Low/High||50.90 / 125.95|
- Retrospective Health Economic Data Published in Advances in Therapy Show Acthar May Be an Important Treatment Option for Patients with Multiple Sclerosis Relapses -
Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.
A rally above $65 with strong volume is needed to change the direction of MNK.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MNK, MTH, TLF, WMB Downgrades: BLMN, TRVN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
- Company will pursue an indication for the drug in treatment of Duchenne Muscular Dystrophy -
-- Patients continuing to receive Acthar in the open label phase maintained the improvements seen in the blinded phase -
Are John Paulson's health care positions all buys? The charts, according to TheStreet's Bruce Kamich, say you may want to wait.
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
- Company's Statewide Collaboration Enables Safe Disposal of Unused Medication for Missouri Families -
Stalking Mallinckrodt for a short and Alcoa for a buy as well.
Left might have changed his mind on Valeant but he's still distrustful of Mallinckrodt and issued a $1 million challenge on the company's premier drug, Acthar.
One day after announcing a long position on Valeant, Andrew Left of Citron Research makes it clear he's still not a fan of Mallinckrodt.
-- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis --
Trade-Ideas LLC identified Mallinckrodt (MNK) as an unusual social activity candidate
Cramer likes Zoe's Kitchen and Celgene and prefers Occidental Petroleum to Devon Energy.
We've seen a volatile market where perception is worse than reality. That's why Cramer is looking at 30 Dow stocks to show you things aren't that bad.
Short ideas on Abercrombie & Fitch, Apple and Mallinckrodt, plus an update on oil.
Trade-Ideas LLC identified Mallinckrodt (MNK) as a "dead cat bounce" (down big yesterday but up big today) candidate
Jim Cramer shares his views on how collateral damage is harming stocks and discusses what the jobs report means. Apple, Amazon and Square are among the stocks discussed here.
But for the brave, they could offer a solid bottom-fishing opportunity.
Trade-Ideas LLC identified Mallinckrodt (MNK) as a weak on high relative volume candidate
Trade-Ideas LLC identified Mallinckrodt (MNK) as a post-market laggard candidate
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Trade-Ideas LLC identified Mallinckrodt (MNK) as a "perilous reversal" (up big yesterday but down big today) candidate
Mallinckrodt (MNK) stock is higher in mid-morning trading on Tuesday after the company released its 2016 second quarter earnings before the market open today.